Virbac Releases New Eight-Way Cattle Vaccine

The company introduces a bovine respiratory disease vaccine alongside a six-month satisfaction guarantee program.

Updated on Oct. 28, 2026 in Pet Health

Virbac Releases New Eight-Way Cattle Vaccine

Live Poll

Is now a good time to switch to broader-spectrum vaccines for your livestock management?

Virbac has launched BOVIGEN Platinum Synvera, an eight-way vaccine designed to protect cattle against key respiratory pathogens. The rollout includes a company-backed satisfaction guarantee for producers.

Why it matters

Bovine respiratory disease remains a significant health challenge for veterinarians and cattle producers. This new vaccine aims to mitigate these impacts through a combination of targeted viral and bacterial protection.

The vaccine provides eight layers of protection against viral and bacterial strains, including BVDV types 1 and 2 and Mannheimia haemolytica. Virbac offers a full refund within 6 months of purchase for unsatisfied customers.

The players

Virbac

Virbac is an international animal health company founded in 1968 that specializes in the development and manufacturing of veterinary products.

The details

The vaccine utilizes an endotoxin-reduction production process to minimize adverse reactions, with study data showing injection site swellings typically reduced within 21 days. It is specifically formulated to combat infectious bovine rhinotracheitis, parainfluenza 3, respiratory syncytial virus, and specific genotypes of P. multocida.

1968: Virbac began operations as an animal health company.
October 28, 2026: Article publication date.

Culture Shift

This launch represents a shift toward more consumer-centric business models within the historically technical veterinary pharmaceutical sector. By offering a satisfaction guarantee, Virbac aligns itself with modern retail expectations for quality and risk mitigation.

Cattle producers can now utilize a new immunization tool that features a clearly defined six-month refund policy if outcomes do not meet expectations. This allows for more financial flexibility when integrating new health protocols into existing herd management routines.

The takeaway

Producers evaluating the vaccine should monitor injection sites for the expected 21-day reduction period for any localized swelling. Utilizing the refund guarantee can provide a lower-risk entry point for testing the efficacy of this new formulation on a specific herd.